title: Clinical applications of attenuated MVA poxvirus strain.
abstract: The highly attenuated poxvirus strain modified vaccinia virus Ankara (MVA) has reached maturity as a vector delivery system and as a vaccine candidate against a broad spectrum of diseases. This has been largely recognized from research on virus-host cell interactions and immunological studies in pre-clinical and clinical trials. This review addresses the studies of MVA vectors used in phase I/II clinical trials, with the aim to provide the main findings obtained on their behavior when tested against relevant human diseases and cancer and also highlights the strategies currently implemented to improve the MVA immunogenicity. The authors assess that MVA vectors are progressing as strong vaccine candidates either alone or when administered in combination with other vectors.
authors.affiliation: Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain.
authors.forename: Carmen Elena
authors.initials: CE
authors.lastname: Gómez
authors.forename: Beatriz
authors.initials: B
authors.lastname: Perdiguero
authors.forename: Juan
authors.initials: J
authors.lastname: García-Arriaza
authors.forename: Mariano
authors.initials: M
authors.lastname: Esteban
mesh_terms: D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D004337:Drug Carriers / Q000008:administration & dosage* / Q000009:adverse effects*; D005822:Genetic Vectors; D006801:Humans; D014612:Vaccines / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology*; D014616:Vaccinia virus / Q000235:genetics*
chemical_list: D004337:Drug Carriers; D014612:Vaccines